ArticleJTCVS open2026
Risk model for mortality in Japanese patients requiring dialysis undergoing transcatheter aortic valve implantation: A report from a Japanese nationwide study.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Transcatheter aortic valve implantation (TAVI) is widely performed. However, the prognosis of patients requiring dialysis undergoing TAVI remains guarded; therefore, we aimed to establish a risk model to predict their prognosis. Methods: A total of 888 patients requiring dialysis underwent TAVI for severe aortic stenosis between February 2021 and March 2022 at 54 facilities in Japan. Patients from 44 randomly selected facilities were included in the development cohort, and the rest were included in the validation cohort. Based on clinical perspective and prior research, 15 preoperative background factors, including the grade of clinical frailty scale (1-3, 4-6, or 7-9) and serum albumin level, were selected and a prognostic model was constructed using Cox proportional hazards regression. Results: The median age of the patients was 80 years (interquartile range, 75-85 years). Three hundred nineteen men (35.9%) and 587 high-risk (Society of Thoracic Surgeons predicted risk of mortality ≥8%) patients (66.1%) were enrolled. The cumulative overall survival rates at 30 days and 1 year after TAVI were 95.9% and 78.3%, respectively. The exacerbated clinical frailty scale was strongly associated with 1-year mortality in the development cohort (hazard ratio, 2.06; 95% CI, 1.47-2.87). Uno's concordance index in the validation cohort was 0.686 (95% CI, 0.588-0.783). Observed survival rates were 91.7% (95% CI, 53.9%-98.8%) in the group with ≥90% predicted survival, 84.8% (95% CI, 70.7%-92.5%) in the group with 80% to <90% predicted survival, and 64.4% (95% CI, 51.9%-74.5%) in the group with <80% predicted survival. Conclusions: The model developed in this study predicts 1-year survival probability, which is useful in considering indications for TAVI in patients requiring dialysis with a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.